Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice.

ABSTRACT:

Objective

To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH).

Methods

There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021. A behavioral neurologist blinded to CSF results assigned a clinical diagnosis retrospectively on the basis of consensus criteria, and a neuroradiologist blinded to the diagnosis and CSF studies graded brain magnetic resonance images for indicators of CSF dynamics disorders. Associations between biomarkers, diagnoses, and imaging were assessed by χ², analysis of covariance, and linear regression me

SUBMITTER: Li W 

PROVIDER: S-EPMC11584168 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature